NCT07087431 Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
| NCT ID | NCT07087431 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2026-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-10-15 with a primary completion date of 2026-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
Eligibility Criteria
Inclusion Criteria: * Current age 30-75 years * Established primary care at Mass General Brigham with at least one visit in the last 2 years Exclusion Criteria: \- Currently taking LDL cholesterol- lowering medications, including statins
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07087431 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 75 Years, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07087431 currently recruiting?
Yes, NCT07087431 is actively recruiting participants. Contact the research team at proact@mgb.org for enrollment information.
Where is the NCT07087431 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07087431 clinical trial?
NCT07087431 is sponsored by Massachusetts General Hospital. The trial plans to enroll 500 participants.